Promethera Extends Series C On Interest From Asian Investors

Dr. John Tchelingerian, CEO of Promethera Biosciences, talks to Scrip senior writer Lucie Ellis on the sidelines of the 2016 BIO-Europe partnering meeting about the company’s liver disease pipeline and series C financing.